Watch: New Cancer Drugs from Artificial Life

In 2014 artificial life was made for the first time.

Two new nucleotides were added—X and Y—to the standard four: A, G, T, C

These new nucleotides allow for the addition of unnatural amino acids to create entirely new kinds of proteins.

Now biotech company Synthorx has announced that they have developed a new cancer drug using these artificial bacteria.

Interleukin-2 has been studied for decades as an immune system-stimulating cancer therapy, but it unfortunately comes with some serious side effects and is often unpredictable.

By adding an extra unnatural amino acid to Interleukin, Synthorx created a “Synthorin” that prolongs the protein’s activity while eliminating its immune-suppressing effects.

So, it turns out that creating artificial life is more than a cool laboratory trick—it may turn out to be a great new way to create new drugs as well.

http://www.sandiegouniontribune.com/business/biotech/sd-me-synthorx-cancer-20180430-story.html

Follow us on social media for the latest updates in B2B!

Image

Latest

career coaching
Work-Based Learning & Career Coaching with Strada Education: Closing the Gap Between Education and Opportunity
February 2, 2026

As higher education faces mounting pressure to demonstrate clear career outcomes, institutions are rethinking how learning connects to work and the role of career coaching in that process. Employers continue to report skills gaps, students are questioning the return on investment of a degree, and states are demanding stronger alignment between postsecondary education and…

Read More
cities
Craftsmanship and the Soul of Cities with Top Real Estate Developer Mike Ablon
February 2, 2026

More than half the world already lives in cities—and the UN projects that share will rise to 68% by 2050, adding roughly 2.5 billion more people to urban areas. At the same time, the “experience economy” has reshaped what people value in places: not just what a city has, but how it feels to…

Read More
client engagement
When Client Engagement Becomes True Partnership
February 1, 2026

CG Infinity’s Salesforce Practice is built on deep, day-to-day engagement with the organizations it serves. Rather than operating as an external vendor, the team embeds itself with clients—working closely, consistently, and collaboratively—so decisions are informed by real context, trust, and shared accountability. This approach ensures Salesforce solutions are shaped not just by requirements, but…

Read More
cross-functional teams
How CG Infinity Brings Cross-Functional Teams Together to Deliver High-Impact Outcomes
February 1, 2026

CG Infinity’s Salesforce Practice is built around helping organizations move forward together, especially when initiatives span cross-functional teams with different priorities. The focus is on alignment—bringing the right stakeholders into the conversation early and ensuring decisions are made collaboratively so solutions serve the whole organization, not just one function. That capability is reflected in a…

Read More